Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MAT2203 · 1 trial · 1 indication
Proportion of cAMB daily dose received and tolerated without vomiting within 30 minutes.
CSF early fungicidal activity (EFA) during 2-week induction therapy
| Arm | Type | Description |
|---|---|---|
| Phase 1a single ascending dose study | EXPERIMENTAL | Phase IA will consist of a single ascending dose study in 9 participants to test three doses to determine the max tolerated dose. |
| Phase 1b multiple day dosing | EXPERIMENTAL | 9 subjects will receive the Phase Ia 100% tolerated MAT2203 dose for 7 days. |
| Phase 2 safety and tolerability | EXPERIMENTAL | Safety, tolerability, and microbiologic efficacy of MAT2203 among HIV-infected patients with cryptococcal meningitis compared with standard IV AMB. |
| Name | Type | Description |
|---|---|---|
| MAT2203 | DRUG | Encochleated amphotericin B |
| Amphotericin B | DRUG | Intravenous amphotericin B |
Inclusion Criteria: * Phase 1: * Age \>18 years * Calculated creatinine clearance \>70 mL/min/1.73 m2 (measured within 3 months) * Written informed consent Phase 2: * Cryptococcal meningitis diagnosed by CSF cryptococcal antigen (CRAG) * Ability and willingness to provide informed consent ...
MAT2203 is an investigational small molecule being developed for the treatment of cryptococcal meningitis, a serious fungal infection of the brain and spinal cord. It is currently in clinical development and has not been approved by regulatory authorities.
MAT2203 is being developed by Matinas Biopharma Holdings, Inc., a biopharmaceutical company traded on the NYSE American under the ticker symbol MTNB. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
MAT2203 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved for commercial use. The Phase 1 trial has been completed, and the drug remains under investigation for cryptococcal meningitis.
MAT2203 has been studied in one completed Phase 1 clinical trial, identified as NCT04031833, titled "Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)." This trial enrolled 178 participants in Uganda and evaluated the drug in patients with cryptococcal meningitis.
MAT2203 is an oral formulation of amphotericin, an antifungal medication. The drug is designed to deliver amphotericin in an encochleated form, which may allow for oral administration. It is being studied as a potential treatment for cryptococcal meningitis.